Pharmaceutical company AstraZeneca, which said it would not take a profit from its COVID-19 vaccines during the pandemic, has now unveiled plans to start selling the shots at “modest profitability.” In its latest financial results published on Friday, AstraZeneca said it is now “expecting to progressively transition the vaccine to modest profitability as new orders are received.” The company said its vaccine sales in the fourth quarter of 2021 will be a blend of the original not-for-profit pandemic agreements and a number of new, for-profit orders. It said that the “limited profit” will offset costs related to its antibody cocktail developed to prevent and treat COVID-19, a disease caused by the CCP (Chinese Communist Party) virus, also known as novel coronavirus. Chief Executive Pascal Sorio told journalists on Friday that the virus was becoming endemic, a term for a background level of infections that is part of everyday life. “We …